INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 136 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2018. The put-call ratio across all filers is 0.51 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $7,315,520 | -17.7% | 140,440 | 0.0% | 0.01% | -25.0% |
Q2 2023 | $8,892,661 | +7.1% | 140,440 | -8.4% | 0.01% | +14.3% |
Q1 2023 | $8,306,339 | -13.1% | 153,395 | -15.1% | 0.01% | -12.5% |
Q4 2022 | $9,560,421 | +0.6% | 180,658 | -11.5% | 0.01% | -11.1% |
Q3 2022 | $9,502,000 | +77.2% | 204,223 | +117.4% | 0.01% | +80.0% |
Q2 2022 | $5,361,000 | +47.2% | 93,919 | +57.8% | 0.01% | +66.7% |
Q1 2022 | $3,641,000 | -14.1% | 59,506 | -52.3% | 0.00% | 0.0% |
Q1 2021 | $4,237,000 | -9.5% | 124,863 | -15.2% | 0.00% | -25.0% |
Q4 2020 | $4,683,000 | +42.6% | 147,265 | +15.1% | 0.00% | +33.3% |
Q3 2020 | $3,283,000 | +5.1% | 127,930 | +5.1% | 0.00% | 0.0% |
Q2 2020 | $3,124,000 | +100.5% | 121,680 | +20.1% | 0.00% | +50.0% |
Q1 2020 | $1,558,000 | -48.6% | 101,348 | +14.6% | 0.00% | -33.3% |
Q4 2019 | $3,033,000 | +478.8% | 88,400 | +26.1% | 0.00% | +200.0% |
Q3 2019 | $524,000 | -31.7% | 70,100 | +18.6% | 0.00% | 0.0% |
Q2 2019 | $767,000 | -43.3% | 59,100 | -46.8% | 0.00% | -50.0% |
Q1 2019 | $1,353,000 | +111.4% | 111,100 | +97.7% | 0.00% | +100.0% |
Q4 2018 | $640,000 | -46.8% | 56,200 | +1.3% | 0.00% | -50.0% |
Q3 2018 | $1,204,000 | +15.3% | 55,505 | -6.1% | 0.00% | +100.0% |
Q2 2018 | $1,044,000 | -3.5% | 59,105 | +15.0% | 0.00% | -50.0% |
Q1 2018 | $1,082,000 | +45.4% | 51,400 | 0.0% | 0.00% | +100.0% |
Q4 2017 | $744,000 | -8.3% | 51,400 | 0.0% | 0.00% | 0.0% |
Q3 2017 | $811,000 | +27.1% | 51,400 | 0.0% | 0.00% | 0.0% |
Q2 2017 | $638,000 | -23.6% | 51,400 | 0.0% | 0.00% | 0.0% |
Q1 2017 | $835,000 | +3.1% | 51,400 | -4.3% | 0.00% | 0.0% |
Q4 2016 | $810,000 | -1.0% | 53,700 | 0.0% | 0.00% | 0.0% |
Q3 2016 | $818,000 | -63.4% | 53,700 | -6.6% | 0.00% | -75.0% |
Q2 2016 | $2,232,000 | +35.4% | 57,500 | -3.0% | 0.00% | +33.3% |
Q1 2016 | $1,649,000 | -61.0% | 59,300 | -24.7% | 0.00% | -57.1% |
Q4 2015 | $4,233,000 | +712.5% | 78,700 | +505.4% | 0.01% | +600.0% |
Q3 2015 | $521,000 | – | 13,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |